Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase inhibitors, such as PD1 immunotherapy, become the key drugs for lung cancer treatment.2 Immunological checkpoint blockade therapies targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4), PD‐1, and PD‐L1 have been shown to have remarkable benefits for the treatment of lung cancer.2 Research by Chae and co‐workers1 showed that the immunophenotype of lung adenocarcinoma (LUAD) can be seen as a primary infiltration by activated CD4 and CD8 cells. This evidence concerns the gene CTLA4 and lung cancer.